In the recent systematic review and meta-analysis by Shelton et al. [21] including 11,702 persons with immune-mediated diseases contributing 31,258 person-years (p-y) of follow-up after a prior diagnosis of cancer, the pooled incidence rate of new or recurrent cancer in patients who received immunosuppressants was 33.8 per 1000 p-y, similar to patients who received anti-TNF or no immunosuppressants. This evidence concerns the gene TNF and cancer.